Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00600821 · ClinicalTrials.gov registry record · Phase 2

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
118
Enrollment target
20
Study locations

NCT00600821: Completed Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma, sponsored by Pfizer.

NCT00600821 is a Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma that has completed, run by Pfizer. The registered enrollment target is 118 participants, below the 232-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00600821, a Phase 2 study of Non-Small-Cell Lung Carcinoma and Adenocarcinoma, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
118 participants
Enrollment target
20
Study locations

Study Summary

To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

Primary Outcome

Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Conditions Studied

Non-Small-Cell Lung Carcinoma Adenocarcinoma

Interventions

  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG AG-013736 (axitinib)

Study Locations (20)

Mississippi

  • Pfizer Investigational Site - Columbus
  • Pfizer Investigational Site - Corinth
  • Pfizer Investigational Site - New Albany
  • Pfizer Investigational Site - Oxford
  • Pfizer Investigational Site - Southaven
  • Pfizer Investigational Site - Tupelo

Texas

  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Lubbock
  • Pfizer Investigational Site - San Antonio

Tennessee

  • Pfizer Investigational Site - Bartlett
  • Pfizer Investigational Site - Germantown
  • Pfizer Investigational Site - Memphis
  • Pfizer Investigational Site - Memphis

Louisiana

  • Pfizer Investigational Site - Baton Rouge

Massachusetts

  • Pfizer Investigational Site - Pittsfield

Nebraska

  • Pfizer Investigational Site - Lincoln

Ohio

  • Pfizer Investigational Site - Cleveland

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2008-04
Est. Completion 2012-10
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT00600821 record still lists

NCT00600821 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 232-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (49% lower).

The record links to 2 conditions, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT00600821 names 20 study sites across 7 states, led by Mississippi, Texas, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00600821 about?

NCT00600821 is a clinical study titled "A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.". To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

What is the current status of trial NCT00600821?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2008-04. Estimated completion is 2012-10.

What conditions does trial NCT00600821 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma.

What interventions are being tested in trial NCT00600821?

The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), AG-013736 (axitinib) (DRUG).

Who is sponsoring clinical trial NCT00600821?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00600821 being conducted?

This trial has 20 study locations across Louisiana, Massachusetts, Mississippi, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00600821's enrollment target sits among peer trials

118 16th of 30 higher than 15 of 30 other Non-Small-Cell Lung Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small-Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821623 · 118 participants · Phase 2

    Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

  • NCT04040959 · 118 participants · Phase 2

    Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

  • NCT04696029 · 118 participants · Phase 2

    DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  • NCT05223192 · 118 participants · NA

    The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00600821, the US trial registry maintained by the National Library of Medicine. NCT00600821 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.